| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-49 |
Sentence |
denotes |
Nebivolol Attenuates Neutrophil Lymphocyte Ratio: |
| T2 |
50-112 |
Sentence |
denotes |
A Marker of Subclinical Inflammation in Hypertensive Patients. |
| T3 |
113-124 |
Sentence |
denotes |
BACKGROUND: |
| T4 |
125-290 |
Sentence |
denotes |
High value of neutrophil lymphocyte ratio (NLR) is a strong independent predictor and biomarker of ongoing vascular inflammation in various cardiovascular disorders. |
| T5 |
291-301 |
Sentence |
denotes |
OBJECTIVE: |
| T6 |
302-451 |
Sentence |
denotes |
The main focus of the study is to investigate the effect of nebivolol on NLR in mild to moderate hypertensive patients in comparison with metoprolol. |
| T7 |
452-573 |
Sentence |
denotes |
In addition, BMI, blood pressure, TLC count, blood sugar, and lipid profile were also assayed before and after treatment. |
| T8 |
574-596 |
Sentence |
denotes |
MATERIALS AND METHODS: |
| T9 |
597-847 |
Sentence |
denotes |
In this 12-week prospective double-blinded randomized study, 120 patients with mild to moderate hypertension were randomly divided into two groups to prescribed daily dose of tab nebivolol 5-10 mg and metoprolol 50-100 mg, respectively, for 12 weeks. |
| T10 |
848-894 |
Sentence |
denotes |
The data were analyzed using SPSS 16 software. |
| T11 |
895-903 |
Sentence |
denotes |
RESULTS: |
| T12 |
904-948 |
Sentence |
denotes |
A total of 100 patients completed the study. |
| T13 |
949-1069 |
Sentence |
denotes |
Both drugs lowered blood pressure significantly, nebivolol 20.5/10.5 and metoprolol 22.5/11.2 (p < 0.001) from baseline. |
| T14 |
1070-1248 |
Sentence |
denotes |
Regarding inflammation, nebivolol reduced total leukocyte count (p = 0.005) and neutrophil count (p = 0.003) and increased lymphocyte count (p = 0.004) as compared to metoprolol. |
| T15 |
1249-1332 |
Sentence |
denotes |
Similarly, nebivolol but not metoprolol significantly reduced NLR ratio (p = 0.07). |
| T16 |
1333-1437 |
Sentence |
denotes |
Nebivolol improved lipid profile and blood sugar compared to metoprolol, but values were nonsignificant. |
| T17 |
1438-1449 |
Sentence |
denotes |
CONCLUSION: |
| T18 |
1450-1559 |
Sentence |
denotes |
Nebivolol has a strong impact on reducing NLR, a marker of subclinical inflammation in hypertensive patients. |
| T19 |
1560-1641 |
Sentence |
denotes |
Moreover NLR can be used as a disease and drug monitoring tool in these patients. |
| T1 |
0-49 |
Sentence |
denotes |
Nebivolol Attenuates Neutrophil Lymphocyte Ratio: |
| T2 |
50-112 |
Sentence |
denotes |
A Marker of Subclinical Inflammation in Hypertensive Patients. |
| T3 |
113-124 |
Sentence |
denotes |
BACKGROUND: |
| T4 |
125-290 |
Sentence |
denotes |
High value of neutrophil lymphocyte ratio (NLR) is a strong independent predictor and biomarker of ongoing vascular inflammation in various cardiovascular disorders. |
| T5 |
291-301 |
Sentence |
denotes |
OBJECTIVE: |
| T6 |
302-451 |
Sentence |
denotes |
The main focus of the study is to investigate the effect of nebivolol on NLR in mild to moderate hypertensive patients in comparison with metoprolol. |
| T7 |
452-573 |
Sentence |
denotes |
In addition, BMI, blood pressure, TLC count, blood sugar, and lipid profile were also assayed before and after treatment. |
| T8 |
574-596 |
Sentence |
denotes |
MATERIALS AND METHODS: |
| T9 |
597-847 |
Sentence |
denotes |
In this 12-week prospective double-blinded randomized study, 120 patients with mild to moderate hypertension were randomly divided into two groups to prescribed daily dose of tab nebivolol 5-10 mg and metoprolol 50-100 mg, respectively, for 12 weeks. |
| T10 |
848-894 |
Sentence |
denotes |
The data were analyzed using SPSS 16 software. |
| T11 |
895-903 |
Sentence |
denotes |
RESULTS: |
| T12 |
904-948 |
Sentence |
denotes |
A total of 100 patients completed the study. |
| T13 |
949-1069 |
Sentence |
denotes |
Both drugs lowered blood pressure significantly, nebivolol 20.5/10.5 and metoprolol 22.5/11.2 (p < 0.001) from baseline. |
| T14 |
1070-1248 |
Sentence |
denotes |
Regarding inflammation, nebivolol reduced total leukocyte count (p = 0.005) and neutrophil count (p = 0.003) and increased lymphocyte count (p = 0.004) as compared to metoprolol. |
| T15 |
1249-1332 |
Sentence |
denotes |
Similarly, nebivolol but not metoprolol significantly reduced NLR ratio (p = 0.07). |
| T16 |
1333-1437 |
Sentence |
denotes |
Nebivolol improved lipid profile and blood sugar compared to metoprolol, but values were nonsignificant. |
| T17 |
1438-1449 |
Sentence |
denotes |
CONCLUSION: |
| T18 |
1450-1559 |
Sentence |
denotes |
Nebivolol has a strong impact on reducing NLR, a marker of subclinical inflammation in hypertensive patients. |
| T19 |
1560-1641 |
Sentence |
denotes |
Moreover NLR can be used as a disease and drug monitoring tool in these patients. |